Related Experiment Videos
New occlusive agent for therapeutic embolization tested in dogs
Cardiovascular and Interventional Radiology
|January 1, 1984
Summary
Vilan 500, a new polyvinyl acetate occlusive agent, effectively embolized kidney arteries in dogs. Histology confirmed complete occlusion and significant tissue damage without recanalization, indicating its potential for renal artery embolization.
Area of Science:
- Interventional Radiology
- Vascular Surgery
- Nephrology
Background:
- Renal artery embolization is a therapeutic option for various kidney conditions.
- Development of effective and safe embolic agents is crucial for successful procedures.
- Vilan 500 is a novel polyvinyl acetate-based agent designed for arterial embolization.
Purpose of the Study:
- To evaluate the efficacy and histological effects of Vilan 500 for renal artery embolization in a canine model.
- To assess the agent's properties, including viscosity and behavior in an aqueous environment.
Main Methods:
- Vilan 500 was used to embolize the renal arterial bed in 12 dogs.
- The agent's low viscosity facilitated delivery via small-caliber catheters.
- Histological examination was performed 4-6 weeks post-procedure to assess tissue changes and vascular patency.
Main Results:
- Complete arterial occlusion of the embolized kidneys was achieved in all subjects.
- Histological findings included renal shrinkage, fibrosis, diffuse necrosis, and atrophic parenchyma.
- No evidence of recanalization or functional collateral circulation was observed.
Conclusions:
- Vilan 500 demonstrates efficacy in achieving complete and durable renal artery occlusion in dogs.
- The observed histological changes suggest significant tissue infarction following embolization.
- The agent's properties are suitable for delivery through catheters, supporting its potential clinical application.